Regulatory & Legal

Frequency Holdings (OTC: FRQN) plants its flag at 14 Wall Street, a high-stakes play for 'optics and access' amid a volatile market position.

A major new report reveals a deepening crisis in rural healthcare, as a $50 billion federal program clashes with devastating cuts, pushing a vital system to the brink.

A new book offers a critical roadmap for medical device developers facing a storm of new AI regulations, complex FDA rules, and evolving IP law.

As schools face driver shortages, a tech firm's 'caregiver on wheels' model for students with special needs gains traction, sparking debate on safety.

OAAA's updated OpenOOH taxonomy brings new clarity to DOOH, aiming to reduce friction, boost buyer confidence, and unlock its role in omnichannel advertising.

A new power standard is emerging to feed AI's insatiable energy needs, promising massive cost savings and efficiency gains for next-gen data centers.

Promising clinical trial results show a new inhaler delivers nicotine as fast as a cigarette, offering a breakthrough for smoking cessation after decades of failure.

InspireSemi schedules a key shareholder update as its Thunderbird I chip, built on RISC-V, aims to challenge NVIDIA and AMD in the AI accelerator market.

Portnox now offers passwordless access for RDP and SSH, tackling the credential theft behind 80% of breaches and accelerating the move away from VPNs.

Axis Communications' new SOC 2 Type 2 certification validates long-term cloud security, raising the standard for trust in the physical security industry.

As AI adoption soars, PwC Canada introduces North America's first Big 4 certification for the ISO 42001 AI standard, aiming to close the trust gap.

New add-on tests from a single blood draw help oncologists avoid toxic chemo reactions and filter out false positives, aiming for safer, smarter cancer care.

FibroBiologics' Pete O'Heeron will speak at the H-SPAN summit, highlighting how cell therapy is driving a push for new healthspan legislation.

With 17 new international pacts, the non-profit now covers over 91% of the global neighboring rights market, simplifying royalty collection for creators.

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

A new lawsuit claims private equity giant TPG hid implant defects and forced a bankruptcy, leaving thousands of injured patients to pay the price.

A new survey shows most family firms expect a leadership change soon, but few are prepared, creating a high-stakes gap between intent and action.

A new partnership between GeminiBio and Tolemy Bio introduces aiMOS™, an AI-powered service designed to cut costs and boost consistency in cell therapy production.

With a new CEO and stunning clinical data, BOOST Pharma advances a potential game-changer for children with the rare genetic disorder Osteogenesis Imperfecta.

With $4.5M donated last year, MAC's iconic lipstick program has evolved from an AIDS crusade into a global force for racial, gender, and environmental justice.